Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Medicinova Announces New Data And Results Of A Phase 2 Clinical Trial Of Mn 166 Ibudilast In Glioblastoma Presented At The 28th Annual Meeting Of The Society For Neuro Oncology is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract ... Read More
MediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001
MediciNova, Inc. announced progress in the enrollment of its key clinical trials for the compounds MN-166 (ibudilast) and MN-001 (tipelukast). The company is nearing the completion of patient ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus